Avivagen Inc
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in the United States, Mex… Read more
Avivagen Inc (VIVXF) - Total Assets
Latest total assets as of July 2023: $272.53K USD
Based on the latest financial reports, Avivagen Inc (VIVXF) holds total assets worth $272.53K USD as of July 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Avivagen Inc - Total Assets Trend (2006–2022)
This chart illustrates how Avivagen Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Avivagen Inc - Asset Composition Analysis
Current Asset Composition (October 2022)
Avivagen Inc's total assets of $272.53K consist of 93.1% current assets and 6.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.3% |
| Accounts Receivable | $572.86K | 42.0% |
| Inventory | $313.96K | 23.0% |
| Property, Plant & Equipment | $94.25K | 6.9% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2022)
This chart illustrates how Avivagen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avivagen Inc's current assets represent 93.1% of total assets in 2022, an increase from 89.1% in 2006.
- Cash Position: Cash and equivalents constituted 21.3% of total assets in 2022, down from 43.3% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 42.0% of total assets.
Avivagen Inc Competitors by Total Assets
Key competitors of Avivagen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Avivagen Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Avivagen Inc generates 0.69x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Avivagen Inc is currently not profitable relative to its asset base.
Avivagen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.81 | 3.01 |
| Quick Ratio | 0.02 | 0.32 | 2.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.22 Million | $ -359.54K | $ 2.03 Million |
Avivagen Inc - Advanced Valuation Insights
This section examines the relationship between Avivagen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -60.7% |
| Total Assets | $1.37 Million |
| Market Capitalization | $7.66K USD |
Valuation Analysis
Below Book Valuation: The market values Avivagen Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Avivagen Inc's assets decreased by 60.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Avivagen Inc (2006–2022)
The table below shows the annual total assets of Avivagen Inc from 2006 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-10-31 | $1.37 Million | -60.74% |
| 2021-10-31 | $3.48 Million | +59.81% |
| 2020-10-31 | $2.18 Million | +15.28% |
| 2019-10-31 | $1.89 Million | -39.29% |
| 2018-10-31 | $3.11 Million | +68.09% |
| 2017-10-31 | $1.85 Million | -64.40% |
| 2016-10-31 | $5.20 Million | +650.13% |
| 2015-10-31 | $692.71K | -20.25% |
| 2014-10-31 | $868.65K | -38.04% |
| 2013-10-31 | $1.40 Million | +254.82% |
| 2012-10-31 | $395.09K | +9.49% |
| 2011-10-31 | $360.84K | -71.44% |
| 2010-10-31 | $1.26 Million | -15.06% |
| 2009-10-31 | $1.49 Million | +142.41% |
| 2008-10-31 | $613.74K | -18.12% |
| 2007-10-31 | $749.57K | +262.10% |
| 2006-10-31 | $207.01K | -- |